Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Recommendation of “Hold” from Brokerages

Novavax, Inc. (NASDAQ:NVAX) has been given a consensus recommendation of “Hold” by the six brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $17.83.

NVAX has been the topic of a number of research analyst reports. Jefferies Financial Group cut their price target on shares of Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, October 16th. HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th.

Insider Activity at Novavax

In other Novavax news, Director Rachel K. King sold 4,150 shares of Novavax stock in a transaction on Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the sale, the director now owns 14,770 shares of the company’s stock, valued at $133,225.40. The trade was a 21.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director James F. Young sold 5,400 shares of Novavax stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total value of $43,200.00. Following the transaction, the director now owns 51,760 shares in the company, valued at approximately $414,080. This represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,150 shares of company stock valued at $119,641. 1.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Novavax

Several institutional investors have recently bought and sold shares of the company. Spire Wealth Management acquired a new position in Novavax in the fourth quarter valued at approximately $29,000. KBC Group NV lifted its stake in Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 3,917 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Novavax by 38.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 1,598 shares during the last quarter. TigerOak Management L.L.C. purchased a new stake in Novavax in the fourth quarter valued at approximately $86,000. Finally, AlphaQuest LLC lifted its stake in Novavax by 290.1% in the fourth quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 7,940 shares during the last quarter. 53.04% of the stock is owned by institutional investors and hedge funds.

Novavax Stock Performance

NVAX stock opened at $8.08 on Wednesday. The company’s fifty day moving average price is $8.77 and its 200-day moving average price is $10.41. Novavax has a one year low of $3.81 and a one year high of $23.86. The company has a market capitalization of $1.29 billion, a PE ratio of -3.58, a price-to-earnings-growth ratio of 63.06 and a beta of 2.14.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.07. The firm had revenue of $84.51 million for the quarter, compared to the consensus estimate of $65.80 million. The company’s revenue was down 54.8% on a year-over-year basis. During the same quarter last year, the firm earned ($1.26) EPS. On average, research analysts predict that Novavax will post -1.31 EPS for the current fiscal year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.